Friday, Apr 26 2024 | Time 02:25 Hrs(IST)
image
Business EconomyPosted at: Oct 27 2016 7:58PM


Pharmexcil condemns Intl report on Indian Pharma

Hyderabad, Oct 27 (UNI) Condemning the recent International report alleging that Indian Pharmaceutical Industry is responsible for causing ‘ Drug Resistant Bacteria (Superbugs), Pharmaceuticals Export Council of India (Pharmexcil), set up by Ministry of Commerce and Industry, under foreign trade policy with an objective to promote the Pharmaceutical exports, today said “ it is clearly a sabotage on Indian Pharma”.
The report put out by UK-based Changing Markets Foundation , alleges that ' Indian Pharmaceutical companies adopt dirty production methods and there are no checks and regulations in place’.
The growth of superbugs (antibiotic resistant bacteria) is a big threat to human safety and that polluting drug companies are contributing to this, it said.
In this regard, the reporting agency has stated that some soil/water samples collected at different places in India (including nearby places of some major Indian Pharmaceutical companies) have shown significant presence of antibiotic resistant bacteria and also made several allegations.
Addressing in a joint press conference, Pharmexcil Director General Dr PV Appaji and Additional Executive Director Mr Ravi uday Bhaskar said Pharmexcil agrees with the fact that there is a serious threat to public health from the emerging ' antibiotic resistance bacteria (superbugs) which is due to various reasons including environmental control.
The Government of India has recently expressed its serious concern and the Indian drug regulator has recently announced some measures to curb excessive / irrational use of antibiotics by medical profession and consumption by patient community.
We are also aware of the impact of antibacterial resistance on India and committed to the cause, they said.
Based on this serious allegation, it is likely to have adverse impact on Indian Pharmaceutical industry in overseas markets, they said and adding that the Pharmexcil has carried out a preliminary assessment of the report and contacted member companies.
The manufacturing facilities of Companies registered in strongly regulated markets like USA and EU are facing very regular audits from respective FDAs and are complying with all requirements.
It is a fact that as on February this year, 631 sites complies with EU GMP, approximately 1400, WHO GMP certified plants and 605 sites are registered with USFDA ( as on April 2015) . It clearly demonstrates the strength and capabilities of Indian pharmaceutical industry, Mr Appaji and Mr Bhaskar said.
Indian Pharmaceutical industry is controlled by a strong regulatory mechanism for GMP and environmental controls. This is being enforced by regular Audits so as to ensure the adherence to the regulatory compliance.
Several International customers are also regularly auditing Environment, Health, and Safety (EHS) systems of manufacturing units of our member companies for compliance with their requirements. Several units also hold ISO 14000 EMS certifications.
They said it looks that the report has selectively targeted and attacking India Pharma , particularly some selected major exports including Aurobiondo, which contributed globally.
UNI KNR CS 2000
Please log in to get detailed story.
Tags: #Pharmexcil condemns Intl report on Indian Pharma
More News

Arun Alagappan appointed as Executive Chairman of Coromandel International

25 Apr 2024 | 7:41 PM

Hyderabad, April 25 (UNI) Arun Alagappan has been appointed as Executive Chairman of Coromandel International Limited (CIL).

see more..

Tech Mahindra net at Rs 661 crore in Q4; Company gives dividend of Rs 28 per share

25 Apr 2024 | 7:28 PM

New Delhi, April 25 (UNI) Mahindra Group company Tech Mahindra, a technology consulting and digital solutions provider, on Thursday reported about 41 per cent decline in net profit at Rs 661 crore year-on-year basis for the fourth quarter ended March 31, 2024.

see more..

Kottayam-Kochi Rubber Market Rates

25 Apr 2024 | 7:26 PM

Kottayam, April 25 (UNI) Following were the Rubber Market rates announced by the Rubber Board here today per quintal.

see more..
Indusind Bank net up 15 pc in Q4

Indusind Bank net up 15 pc in Q4

25 Apr 2024 | 7:10 PM

New Delhi, April 25 (UNI) Leading private bank Indusind on Thursday reported a 15 percent jump in net profit at Rs 2,349 crore in Q4 of FY 2023–24, compared to Rs 2,043 crore in the same quarter in 2022–23.

see more..

25 Apr 2024 | 6:53 PM

New Delhi, April 25 (UNI) Leading private bank Indusind on Thursday reported 15 percent jump in net profit at Rs 2,349 crore in Q4 of FY 2023-24 compared to Rs 2,043 crore in the same quarter in 2022-23.

see more..
image